Fractalkine signaling regulates the inflammatory response in an α-synuclein model of Parkinson disease

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Thome, Aaron D ^a   Standaert, David G ^a   Harms, Ashley S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, MOUSE; CX3CR1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL LOSS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; DOPAMINERGIC NERVE CELL; IMMUNOGLOBULIN DEPOSITION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PROTEIN AGGREGATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; DEPENDOPARVOVIRUS; DRUG EFFECTS; GENE INACTIVATION; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM;

ALPHA-SYNUCLEIN; ANIMALS; CHEMOKINE CX3CL1; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GENE KNOCKOUT TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; MICROGLIA; PARKINSON DISEASE; PHAGOCYTOSIS; RECEPTORS, CHEMOKINE;

EID: 84948970708     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140566     Document Type: Article

References (35)

1. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047. PMID: 9197268
2. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, et al. (2008) Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 63: 743-750. doi: 10.1002/ana.21380 PMID: 18571778
3. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46: 989-993. doi: 10.1038/ng.3043 PMID: 25064009
4. Appel SH (2012) Inflammation in Parkinson's disease: cause or consequence? Mov Disord 27: 1075-1077. doi: 10.1002/mds.25111 PMID: 22806694
5. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8: 382-397. doi: 10.1016/S1474-4422(09)70062-6 PMID: 19296921
6. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291. PMID: 3399080
7. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, et al. (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180: 147-150. PMID: 7700568
8. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, et al. (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208-210. PMID: 8015728
9. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, et al. (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21: 404-412. PMID: 16182554
10. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, et al. (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119: 182-192. doi: 10.1172/JCI36470 PMID: 19104149
11. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, et al. (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42: 781-785. doi: 10.1038/ng.642 PMID: 20711177
12. Allen Reish HE, Standaert DG (2015) Role of alpha-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease. J Parkinsons Dis.
13. Ramsey CP, Tansey MG (2014) A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets. Exp Neurol 256: 126-132. doi: 10.1016/j.expneurol.2013.05.014 PMID: 23726958
14. Cao S, Theodore S, Standaert DG (2010) Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol Neurodegener 5:42. doi: 10.1186/1750-1326-5-42 PMID: 20977765
15. Harms AS, Cao S, Rowse AL, Thome AD, Li X, et al. (2013) MHCII Is Required for alpha-Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration. J Neurosci 33: 9592-9600. doi: 10.1523/JNEUROSCI.5610-12.2013 PMID: 23739956
16. Sheridan GK, Murphy KJ (2013) Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol 3: 130181. doi: 10.1098/rsob.130181 PMID: 24352739
17. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, et al. (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 95: 10896-10901. PMID: 9724801
18. Cook DN, Chen SC, Sullivan LM, Manfra DJ, Wiekowski MT, et al. (2001) Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol 21: 3159-3165. PMID: 11287620
19. Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27: 119-145. doi: 10.1146/annurev.immunol.021908.132528 PMID: 19302036
20. Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff RM, et al. (2012) The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol 188: 29-36. doi: 10.4049/jimmunol.1100421 PMID: 22079990
21. Limatola C, Ransohoff RM (2014) Modulating neurotoxicity through CX3CL1/CX3CR1 signaling. Front Cell Neurosci 8: 229. doi: 10.3389/fncel.2014.00229 PMID: 25152714
22. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, et al. (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9: 917-924. PMID: 16732273
23. Nash KR, Lee DC, Hunt JB Jr., Morganti JM, Selenica ML, et al. (2013) Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging 34: 1540-1548. doi: 10.1016/j. neurobiolaging.2012.12.011 PMID: 23332170
24. Cao S, Standaert DG, Harms AS (2012) The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. J Neuroinflammation 9: 259. doi:10. 1186/1742-2094-9-259 PMID: 23186369
25. St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, et al. (2007) Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 100: 1449-1457. PMID: 17241127
26. Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67: 1149-1158. doi: 10.1097/NEN.0b013e31818e5e99 PMID: 19018246
27. Harms AS, Lee JK, Nguyen TA, Chang J, Ruhn KM, et al. (2012) Regulation of microglia effector functions by tumor necrosis factor signaling. Glia 60: 189-202. doi: 10.1002/glia.21254 PMID: 21989628
28. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128: 2665-2674. PMID: 16219675
29. Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, et al. (2010) CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol 177: 2549-2562. doi: 10.2353/ajpath.2010.100265 PMID: 20864679
30. Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC (2011) CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation 8:9. doi: 10.1186/1742-2094-8-9 PMID: 21266082
31. Morganti JM, Nash KR, Grimmig BA, Ranjit S, Small B, et al. (2012) The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease. J Neurosci 32: 14592-14601. doi: 10.1523/JNEUROSCI.0539-12.2012 PMID: 23077045
32. Wang Y, Fu Y, Xue S, Ai A, Chen H, et al. (2014) The M2 polarization of macrophage induced by fractalkine in the endometriotic milieu enhances invasiveness of endometrial stromal cells. Int J Clin Exp Pathol 7: 194-203. PMID: 24427339
33. Cho SH, Sun B, Zhou Y, Kauppinen TM, Halabisky B, et al. (2011) CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem 286: 32713-32722. doi: 10.1074/jbc.M111.254268 PMID: 21771791
34. Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, et al. (2010) Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci 13: 411-413. doi: 10.1038/nn.2511 PMID: 20305648
35. Nash KR, Moran P, Finneran DJ, Hudson C, Robinson J, et al. (2015) Fractalkine Over Expression Suppresses alpha-Synuclein-mediated Neurodegeneration. Mol Ther 23: 17-23. doi: 10.1038/mt. 2014.175 PMID: 25195598